Patient Guide: A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 47 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06772623
Status: 🟢 Enrolling Now
Condition: Non Small Cell Lung Carcinoma
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 47 locations across the country.

Top locations include:
  • • Fullerton, California
  • • Oxnard, California
  • • Aurora, Colorado
  • • And 44 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations - Join Clinical Trial NCTNCT06772623

How to Join This Clinical Trial - NCTNCT06772623

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Non Small Cell Lung Carcinoma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Non Small Cell Lung Carcinoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Non Small Cell Lung Carcinoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06772623 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 47 locations. Find a study site near you:

Clinical Research Site

Fullerton, California 92835 - United States

Status: RECRUITING

Clinical Research Site

Oxnard, California 93030 - United States

Status: RECRUITING

Clinical Research Site

Aurora, Colorado 80045 - United States

Status: RECRUITING

Clinical Research Site

Lone Tree, Colorado 80124 - United States

Status: RECRUITING

Clinical Research Site

Orange City, Florida 32763 - United States

Status: RECRUITING

Clinical Research Site

Hinsdale, Illinois 60521 - United States

Status: RECRUITING

Clinical Research Site

Indianapolis, Indiana 46202 - United States

Status: RECRUITING

Clinical Research Site

East Brunswick, New Jersey 08816-4096 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10028 - United States

Status: RECRUITING

Clinical Research Site

Cleveland, Ohio 44106 - United States

Status: RECRUITING

And 37 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Non Small Cell Lung Carcinoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships